AstraZeneca, Merck secure FDA nod for pancreatic cancer drug Lynparza

This article was originally published here

The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease

The post AstraZeneca, Merck secure FDA nod for pancreatic cancer drug Lynparza appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply